SCHEMBL15833535

SCHEMBL15833535

Cc1ncc2ccn(C3CCNCC3)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 7/20 0.39
CHEK1 O14757 6/20 0.39
AURKA O14965 4/20 0.39
CDK4 P11802 3/20 0.39
INSR P06213 1/20 0.39
CDK1 P06493 1/20 0.39
PDGFRB P09619 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
CDK7 P50613 1/20 0.39
NTRK2 Q16620 1/20 0.39
PRMT5 O14744 1/20 0.38
TTK P33981 2/20 0.38
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
MAPK8 P45983 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513398 0.86 AURKA (0.46) AURKACDK4INSRCDK1PDGFRB
SCHEMBL15833536 0.85 PRMT5 (0.36) AURKACDK4INSRCDK1PDGFRB
SCHEMBL19928091 0.82 CHEK2 (0.38) CHEK2CHEK1AURKACDK4INSR
SCHEMBL20135232 0.78 CHEK2 (0.42) CHEK2CHEK1TTKJAK2JAK1
SCHEMBL15833537 0.77 PRMT5 (0.45) AURKACDK4INSRCDK1PDGFRB
SCHEMBL16280901 0.77 JAK2 (0.47) CHEK2CHEK1AURKAKDRJAK2
SCHEMBL29688584 0.70 CHEK2 (0.37) CHEK2CHEK1SRCJAK2JAK1
SCHEMBL20135304 0.70 CHEK2 (0.37) CHEK2CHEK1SRCJAK2JAK1
SCHEMBL30480564 0.70 AURKA (0.41) AURKACDK4INSRCDK1PDGFRB
SCHEMBL27033337 0.70 AURKA (0.41) AURKACDK4INSRCDK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777008-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-10-03 US disclosed
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-04-27 US disclosed
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-07-28 US disclosed
US-9388173-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2016-07-12 US disclosed
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-05-14 US disclosed
US-8906900-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2014-12-09 US disclosed
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-08-14 US disclosed
WO-2014100695-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 CHEK2 565/4885CHEK1 910/4885AURKA 1542/4885
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 CHEK2 567/4885CHEK1 920/4885AURKA 1174/4885
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 CHEK2 565/4885CHEK1 910/4885AURKA 1542/4885
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 CHEK2 565/4885CHEK1 910/4885AURKA 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.